Immune-mediated inflammatory diseases (IMIDs) of the joints, gut and skin are treated with inhibitors of inflammatory cytokines. These cytokines are involved in the pathogenesis of coronavirus disease 2019 (COVID-19). Investigating anti-SARS-CoV-2 antibody responses in IMIDs we observe a reduced incidence of SARS-CoV-2 seroconversion in IMID patients treated with cytokine inhibitors compared to patients receiving no such inhibitors and two healthy control populations, despite similar social exposure. Hence, cytokine inhibitors seem to at least partially protect from SARS-CoV-2 infection. Cytokine storm seems to be a common feature of severe COVID-19 pathology. Here, the authors show a reduced rate of SARS-CoV2 positivity in a large population of patients with immune-mediated inflammatory diseases if they are already being treated with cytokine or JAK inhibitors, indicating these treatments are safe to continue and are possibly protective against COVID19.
【저자키워드】 viral infection, Epidemiology, rheumatoid arthritis, Crohn's disease, 【초록키워드】 COVID-19, Treatment, coronavirus disease, SARS-CoV-2, pathology, SARS-CoV2, COVID19, Pathogenesis, severe COVID-19, SARS-COV-2 infection, cytokine, Seroconversion, anti-SARS-CoV-2 antibody, response, Patient, jak inhibitors, Inflammatory cytokines, incidence, inhibitor, Protective, Gut, Safe, healthy control, inflammatory disease, joints, Immune-mediated inflammatory disease, populations, observé, PROTECT, involved, receiving, reduced, treated, cytokine inhibitor, patients treated, 【제목키워드】 SARS-CoV-2, Prevalence, Seroconversion, Immune-mediated inflammatory disease, receiving, cytokine inhibitor,